| Identification | More | [Name]
Glatiramer acetate | [CAS]
147245-92-9 | [Synonyms]
GLATIRAMER ACETATE
l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt) | [EINECS(EC#)]
814-981-5 | [Molecular Formula]
C25H45N5O13 | [MDL Number]
MFCD04113403 | [MOL File]
147245-92-9.mol | [Molecular Weight]
623.65 |
| Hazard Information | Back Directory | [Uses]
Glatiramer acetate is a random basic synthetic copolymer of L-alanine, L-lysine, l-glutamic acid and L-tyrosine in a molar ratio of 6:1.9:4.7:1. Glatiramer acetate is an immunomodulator used in treatment of multiple sclerosis. | [Originator]
Copaxone,Teva Pharmaceuticals,Israel | [Manufacturing Process]
Glatiramer Acetate is water soluble copolypeptide with molecular weight
15,000-25,000.
Copolymer is prepared by copolymerization of the N-carboxyanhydrides of
tyrosine, alanine, lysine, and glutamic acid. The polymerisation was carried
out at ambient temperature in anhydrous dioxane with diethylamine as
initiator. Glatiramer Acetate have the ratio alanin:glutamic acid:lysine:tyrosine
= 1:6:4.54:2. | [Brand name]
Copaxone (Teva). | [Therapeutic Function]
Immunomodulator | [Clinical Use]
Immunomodulating drug:
Treatment for patients at a high risk of developing
multiple sclerosis and for reduction in relapses in
ambulatory patients | [Drug interactions]
Potentially hazardous interactions with other drugs
None known | [Metabolism]
A substantial fraction of a subcutaneous dose of
glatiramer is believed to be hydrolysed locally. Some of
the injected dose is also presumed to enter the lymphatic
system, either intact or partially hydrolysed. |
|
|